Q3 2025 DaVita Inc Earnings Call Transcript
Key Points
- DaVita Inc (DVA) delivered third-quarter adjusted operating income of $517 million and adjusted earnings per share of $2.51, consistent with internal expectations.
- The company reaffirmed its full-year guidance for adjusted operating income and adjusted earnings per share, indicating confidence in meeting annual targets.
- DaVita Clinical Research (DCR) continues to advance kidney care research, maintaining over 250 research sites and contributing to more than 700 clinical publications.
- Investments in technology infrastructure, including AI solutions, are expected to enhance clinical care and drive long-term cost efficiencies.
- The company is actively working on improving patient outcomes through innovations like middle molecule clearance, which could significantly advance patient care.
- US treatment volume was down approximately 1.5% year-over-year, impacted by factors such as Hurricane Helene, a severe flu season, and a cyber incident.
- Patient care costs per treatment increased by approximately $5 sequentially, driven by wage increases and higher pharmaceutical expenses.
- The payer mix showed a slight decline, contributing to variability in revenue per treatment.
- The Integrated Kidney Care (IKC) segment reported an adjusted operating loss of $21 million in Q3, with timing of revenue recognition remaining unpredictable.
- The company faces uncertainties in 2026 related to volume, payer mix, and policy changes, which could impact financial performance.
Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita third-quarter 2025 earnings call. (Operator Instructions)
Thank you. Mr. Eliason, you may begin your conference, sir.
Thank you, and welcome to our third-quarter conference call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations. And joining me today are Javier Rodriguez, our CEO; and Joel Ackerman, our CFO.
Please note that during this call, we may make forward-looking statements within the meaning of the Federal Securities Laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements.
For further details concerning these risks and uncertainties, please refer to our third-quarter earnings press release and our SEC filings, including our most recent
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
